- Revive Therapeutics (RVV) has closed a private placement for gross proceeds of $4.3 million
- The company issued 28,676,064 units priced at C$0.15 per unit
- The company paid finders fees totalling $304,112.75 in cash and 2,294,085 finder warrants
- Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders
- Revive Therapeutics Ltd. (RVV) opened trading at C$0.13
Revive Therapeutics (RVV) has closed its previously-announced private placement for gross proceeds of$4,301,409.
The company issued a total of 28,676,064 units for $0.15 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share for a period of three years from the closing date of the offering.
The company paid $304,112.75 in cash and 2,294,085 finder warrants to EMD Financial Inc. and other registrants.
The offering is subject to the receipt of all necessary regulatory approvals.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders.
Revive Therapeutics Ltd. (RVV) opened trading at C$0.13.
